BioCentury | Sep 15, 2020
Deals

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

...Merck deals give Seattle Genetics $725M in cash, $1B...
...over Seattle Genetics’ close of $149.97 on Friday. Seattle Genetics...
...the program.” Clay Siegall, Seattle Genetics Merck and Seattle Genetics...
BioCentury | Sep 15, 2020
Deals

$21B deal by Gilead, none by PhRMA: a BioCentury podcast

...nearly 40 years as an independent company, $1.5 billion raised and a scuttled deal with Seattle Genetics...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...issues.Nearly two years prior, a deal granting Seattle Genetics Inc....
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

...of that program. Yes, we are doing that massively. We're also doing it together with Seattle Genetics...
BioCentury | Jul 10, 2020
Regulation

Ocular toxicity assessment stands between multiple myeloma patients and the first BCMA approval

...populations, so a bystander effect is possible. Last year, FDA approved Padcev enfortumab vedotin-ejfv from Seattle Genetics Inc....
...CD269) - Tumor necrosis factor receptor superfamily 17 Lauren Martz Senior Editor belantamab mafodotin, J6M0-mcMMAF (2857916, GSK2857916) GlaxoSmithKline plc Seattle Genetics Inc. Tumor...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

...with incomplete blood count recovery and 2 partial remissions. Phase II signal for tisotumab vedotin Seattle Genetics Inc....
...tissue factor-targeting antibody-drug conjugate (ADC) also had a median duration of response of 8.3 months. Seattle Genetics...
BioCentury | Apr 18, 2020
Regulation

Trio of approvals includes Seattle Genetics’ breast cancer therapy

...Just two months after granting Priority Review to Seattle Genetics’ Tukysa tucatinib, FDA approved the drug as...
...in patients who have received one or more prior anti-HER2 regimens in the metastatic setting. Seattle Genetics Inc....
...showed Tukysa increased progression-free survival and overall survival compared with Herceptin and capecitabine alone (see “Seattle Genetics...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

...CAR T therapies. Seattle Genetics sees accelerated approval path for ADC Based on discussions with FDA, Seattle Genetics Inc....
...PRR4 - Nectin-4 BioCentury Staff Keytruda, pembrolizumab (MK-3475, lambrolizumab) Merck & Co. Inc. Novartis AG Aurobindo Pharma Ltd. Kite Pharma Inc. TeneoBio Inc. Seattle Genetics Inc. Lysophosphatidic...
BioCentury | Mar 3, 2020
Product Development

March 2 Quick Takes: FDA Priority Review for MorphoSys-Incyte lymphoma therapy; plus Pfizer-Lilly, Merck, AbbVie, Novartis, Cerovene

...The anti-PD-1 mAb improved progression-free survival compared with Adcetris brentuximab vedotin, an antibody-drug conjugate from Seattle Genetics Inc....
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

...August decision dates for BMS, Seattle Genetics, Deciphera A trio of cancer therapies have received Priority Review...
...acquisition of Celgene Corp. The PDUFA date is Aug. 17. An NDA for tucatinib from Seattle Genetics Inc....
...Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Bristol-Myers Squibb Co. Celgene Corp. Juno Therapeutics Inc. Seattle Genetics Inc. Deciphera...
Items per page:
1 - 10 of 853
BioCentury | Sep 15, 2020
Deals

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

...Merck deals give Seattle Genetics $725M in cash, $1B...
...over Seattle Genetics’ close of $149.97 on Friday. Seattle Genetics...
...the program.” Clay Siegall, Seattle Genetics Merck and Seattle Genetics...
BioCentury | Sep 15, 2020
Deals

$21B deal by Gilead, none by PhRMA: a BioCentury podcast

...nearly 40 years as an independent company, $1.5 billion raised and a scuttled deal with Seattle Genetics...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...issues.Nearly two years prior, a deal granting Seattle Genetics Inc....
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

...of that program. Yes, we are doing that massively. We're also doing it together with Seattle Genetics...
BioCentury | Jul 10, 2020
Regulation

Ocular toxicity assessment stands between multiple myeloma patients and the first BCMA approval

...populations, so a bystander effect is possible. Last year, FDA approved Padcev enfortumab vedotin-ejfv from Seattle Genetics Inc....
...CD269) - Tumor necrosis factor receptor superfamily 17 Lauren Martz Senior Editor belantamab mafodotin, J6M0-mcMMAF (2857916, GSK2857916) GlaxoSmithKline plc Seattle Genetics Inc. Tumor...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

...with incomplete blood count recovery and 2 partial remissions. Phase II signal for tisotumab vedotin Seattle Genetics Inc....
...tissue factor-targeting antibody-drug conjugate (ADC) also had a median duration of response of 8.3 months. Seattle Genetics...
BioCentury | Apr 18, 2020
Regulation

Trio of approvals includes Seattle Genetics’ breast cancer therapy

...Just two months after granting Priority Review to Seattle Genetics’ Tukysa tucatinib, FDA approved the drug as...
...in patients who have received one or more prior anti-HER2 regimens in the metastatic setting. Seattle Genetics Inc....
...showed Tukysa increased progression-free survival and overall survival compared with Herceptin and capecitabine alone (see “Seattle Genetics...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

...CAR T therapies. Seattle Genetics sees accelerated approval path for ADC Based on discussions with FDA, Seattle Genetics Inc....
...PRR4 - Nectin-4 BioCentury Staff Keytruda, pembrolizumab (MK-3475, lambrolizumab) Merck & Co. Inc. Novartis AG Aurobindo Pharma Ltd. Kite Pharma Inc. TeneoBio Inc. Seattle Genetics Inc. Lysophosphatidic...
BioCentury | Mar 3, 2020
Product Development

March 2 Quick Takes: FDA Priority Review for MorphoSys-Incyte lymphoma therapy; plus Pfizer-Lilly, Merck, AbbVie, Novartis, Cerovene

...The anti-PD-1 mAb improved progression-free survival compared with Adcetris brentuximab vedotin, an antibody-drug conjugate from Seattle Genetics Inc....
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

...August decision dates for BMS, Seattle Genetics, Deciphera A trio of cancer therapies have received Priority Review...
...acquisition of Celgene Corp. The PDUFA date is Aug. 17. An NDA for tucatinib from Seattle Genetics Inc....
...Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Bristol-Myers Squibb Co. Celgene Corp. Juno Therapeutics Inc. Seattle Genetics Inc. Deciphera...
Items per page:
1 - 10 of 853